||Recombinant Human Ret Proto-oncogene with a C-terminal His tag was expressed in an insect cell line,Sf 21.
||The RET proto-oncogene encodes a receptor tyrosine kinase for members of the glial cell line-derived neurotrophic factor family of extracellular signalling molecules. RET loss of function mutations are associated with the development of Hirschsprung"s disease, while gain of function mutations are associated with the development of various types of human cancer, including medullary thyroid carcinoma, multiple endocrine neoplasias type 2A and 2B, phaeochromocytoma and parathyroid hyperplasia.
||> 90%, as determined by SDS-PAGE and visualized by silver stain.
||Based on N-terminal sequencing, mature recombinant human Ret starts at Leu 29 and has a calculated mass of 69 kDa. As a result of glycosylation, the recombinant monomeric protein migrates as an approximately 90 kDa protein in SDS-PAGE under reducing conditions.
||Measured by its ability to bind the complex of Artemin-GFRα3 in a functional ELISA. Serial dilution of immobilized rhRet (100μL/well) was tested for binding with rmArtemin (10 ng/mL) in the presence of rhGFRα3/Fc (2 μg/mL). The ED50 of the immobilized Ret in this assay is typically2 - 6 μg/mL.
||< 2.0 EU per 1 μg of the enzyme as determined by the LAL method.
||Lyophilized from a 0.2 μm filtered solution in PBS containing 50 μg of bovine serum albumin per 1 μg of cytokine.
||Lyophilized samples are stable for up to six months at -20°C to -70°C. Upon reconstitution, this cytokine, in the presence of a carrier protein, can be stored under sterile conditions at 2 - 8°C for one month or at -20°C to -70°C in a manual defrost freezer for three months without detectable loss of activity. Avoid repeated freeze-thaw cycles.